SEDIA BIOSCIENCES CORPORATION — Department of Health and Human Services SBIR Phase II: DESCRIPTION (provided by applicant): The objectives of this project are to develop a comme
SEDIA BIOSCIENCES CORPORATION — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,000,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- OR
- Period
- —
Description
DESCRIPTION (provided by applicant): The objectives of this project are to develop a commercial single well HIV-1 Limiting Antigen Avidity EIA, developed in Phase I as a research tool, and establish its suitability for identifying recent HIV-1 infections on both a population an on an individual clinical basis as an aid to early intervention in acute infections. Such methods are needed for accurate measures of the incidence of new HIV infections to enable monitoring of the epidemic in populations, optimal targeting of public health resources and assessment of intervention effectiveness. In addition, identification of persons recently infected is important a these persons are typically hyper-infectious and at greater risk of transmitting the disease to partners. The scientific literature estimates that nearly half of all infections are transmitted frm partners who themselves are recent infections. Such high risk individuals should be aggressively identified treated, counseled and contact-traced to immediat